TY - JOUR
T1 - A Multilayered Mesoporous Gold Nanoarchitecture for Ultraeffective Near-Infrared Light-Controlled Chemo/Photothermal Therapy for Cancer Guided by SERS Imaging
AU - Yin, Bohan
AU - Ho, Willis Kwun Hei
AU - Xia, Xinyue
AU - Chan, Cecilia Ka Wing
AU - Zhang, Qin
AU - Ng, Yip Ming
AU - Lam, Ching Ying Katherine
AU - Cheung, James Chung Wai
AU - Wang, Jianfang
AU - Yang, Mo
AU - Wong, Siu Hong Dexter
N1 - Funding Information:
This work was supported by the Shenzhen‐Hong Kong‐Macao Science and Technology Plan Project (Category C, SGDX2020110309260000), Shenzhen Science and Technology Program (JCYJ20220531090808020), the innovation and Technology Commission Guangdong‐Hong Kong Technology Cooperation Funding Scheme (GHP/032/20SZ) and the Research Grants Council (RGC) of Hong Kong Collaborative Research Grant (C5078‐21EF). S.H.D.W. acknowledges the Start‐up Funding (0033912) from the Department of Biomedical Engineering and Start‐up Fund for RAPs under the Strategic Hiring Scheme (0035876), the Hong Kong Polytechnic University (PolyU, University Grant Council), and PolyU Projects of RISports (A0043522) for supporting this work. This work was also supported by the National Natural Science Foundation of China (NSFC) (grant nos. 31771077), the Research Grants Council (RGC) of Hong Kong General Research Grant (PolyU 15214619 and PolyU 15217621), and the Hong Kong Polytechnic University Internal Fund (1‐ ZVVQ). This work was also supported by the University Research Facility in Life Sciences of PolyU.
Funding Information:
This work was supported by the Shenzhen-Hong Kong-Macao Science and Technology Plan Project (Category C, SGDX2020110309260000), Shenzhen Science and Technology Program (JCYJ20220531090808020), the innovation and Technology Commission Guangdong-Hong Kong Technology Cooperation Funding Scheme (GHP/032/20SZ) and the Research Grants Council (RGC) of Hong Kong Collaborative Research Grant (C5078-21EF). S.H.D.W. acknowledges the Start-up Funding (0033912) from the Department of Biomedical Engineering and Start-up Fund for RAPs under the Strategic Hiring Scheme (0035876), the Hong Kong Polytechnic University (PolyU, University Grant Council), and PolyU Projects of RISports (A0043522) for supporting this work. This work was also supported by the National Natural Science Foundation of China (NSFC) (grant nos. 31771077), the Research Grants Council (RGC) of Hong Kong General Research Grant (PolyU 15214619 and PolyU 15217621), and the Hong Kong Polytechnic University Internal Fund (1- ZVVQ). This work was also supported by the University Research Facility in Life Sciences of PolyU.
Publisher Copyright:
© 2023 Wiley-VCH GmbH.
PY - 2023/2/8
Y1 - 2023/2/8
N2 - Surface-enhanced Raman scattering (SERS) imaging has emerged as a promising tool for guided cancer diagnosis and synergistic therapies, such as combined chemotherapy and photothermal therapy (chemo-PTT). Yet, existing therapeutic agents often suffer from low SERS sensitivity, insufficient photothermal conversion, or/and limited drug loading capacity. Herein, a multifunctional theragnostic nanoplatform consisting of mesoporous silica-coated gold nanostar with a cyclic Arg-Gly-Asp (RGD)-coated gold nanocluster shell (named RGD–pAS@AuNC) is reported that exhibits multiple “hot spots” for pronouncedly enhanced SERS signals and improved near-infrared (NIR)-induced photothermal conversion efficiency (85.5%), with a large capacity for high doxorubicin (DOX) loading efficiency (34.1%, named RGD/DOX–pAS@AuNC) and effective NIR-triggered DOX release. This nanoplatform shows excellent performance in xenograft tumor model of HeLa cell targeting, negligible cytotoxicity, and good stability both in vitro and in vivo. By SERS imaging, the optimal temporal distribution of injected RGD/DOX–pAS@AuNCs at the tumor site is identified for NIR-triggered local chemo-PTT toward the tumor, achieving ultraeffective therapy in tumor cells and tumor-bearing mouse model with 5 min of NIR irradiation (0.5 W cm−2). This work offers a promising approach to employing SERS imaging for effective noninvasive tumor treatment by on-site triggered chemo-PTT.
AB - Surface-enhanced Raman scattering (SERS) imaging has emerged as a promising tool for guided cancer diagnosis and synergistic therapies, such as combined chemotherapy and photothermal therapy (chemo-PTT). Yet, existing therapeutic agents often suffer from low SERS sensitivity, insufficient photothermal conversion, or/and limited drug loading capacity. Herein, a multifunctional theragnostic nanoplatform consisting of mesoporous silica-coated gold nanostar with a cyclic Arg-Gly-Asp (RGD)-coated gold nanocluster shell (named RGD–pAS@AuNC) is reported that exhibits multiple “hot spots” for pronouncedly enhanced SERS signals and improved near-infrared (NIR)-induced photothermal conversion efficiency (85.5%), with a large capacity for high doxorubicin (DOX) loading efficiency (34.1%, named RGD/DOX–pAS@AuNC) and effective NIR-triggered DOX release. This nanoplatform shows excellent performance in xenograft tumor model of HeLa cell targeting, negligible cytotoxicity, and good stability both in vitro and in vivo. By SERS imaging, the optimal temporal distribution of injected RGD/DOX–pAS@AuNCs at the tumor site is identified for NIR-triggered local chemo-PTT toward the tumor, achieving ultraeffective therapy in tumor cells and tumor-bearing mouse model with 5 min of NIR irradiation (0.5 W cm−2). This work offers a promising approach to employing SERS imaging for effective noninvasive tumor treatment by on-site triggered chemo-PTT.
KW - controlled drug release
KW - mesoporous nanostructures
KW - photothermal therapy
KW - plasmonic nanomaterials
KW - surface-enhanced Raman spectroscopy
UR - http://www.scopus.com/inward/record.url?scp=85145382584&partnerID=8YFLogxK
U2 - 10.1002/smll.202206762
DO - 10.1002/smll.202206762
M3 - Journal article
C2 - 36593512
AN - SCOPUS:85145382584
SN - 1613-6810
VL - 19
JO - Small
JF - Small
IS - 6
M1 - 2206762
ER -